Jim Pearce

Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.

Analyst Articles

An update for all subscribers who still own the VF Corporation August 62.5 puts (initial sale Alert was issued last week). The stock continues to drift lower and the puts traded at $1.83 this morning, close to the $1.90 high from last week. I think this is a good exit… Read More

Argos Therapeutics (ARGS) announced yesterday evening the terms of its upcoming secondary stock offering, which has sent its share price down more than 15% this morning to partially offset the dilution that will occur after the offering has been completed. The company intends to raise $50 million compared to its… Read More

Cancer immunotherapy company ZIOPHARM Oncology (ZIOP) disclosed on July 15th that a patient in one of its brain cancer trial groups died after being treated with its experimental drug treatment, and two other patients also passed away for reasons unrelated to this form of therapy. As we noted… Read More

Old Tech Firms: The New Bonds

A trio of “old tech” companies reported quarterly earnings this week, which in the past would have drew yawns from stock market analysts. But with overseas investors fleeing the uncertainty of Europe and Asia for the relative security of the United States, many of these stocks have become de facto… Read More

When we launched Breakthrough Tech Profits two months ago, we knew our stock picks were good, but we also thought our timing was, too. We expected a flood of investor money would soon flow into technology-intensive companies that could generate bigger profits in a stagnant global economy. Still, we didn’t… Read More

It wasn’t long ago that investors couldn’t run away from Western Digital (WDC) fast enough. The darling of contrarian tech investors only two years ago as its share price soared above $100, rapidly declining sales of PCs during the past year and concerns over the price Western Digital paid to… Read More

M&A Goes to the Next Level

If you like to profit from mergers and acquisitions, consider investing in our cash-flow rich Personal Finance Growth portfolio stocks. Last week I discussed how Danone’s buyout offer for WhiteWave Foods was an example of the merger and acquisition activity that the Brexit vote will spawn as nervous executives in Europe look to buy… Read More

In the inaugural issue of Breakthrough Tech Profits, I recommended disk drive manufacturer Western Digital (WDC) as a play on growth in the SSD (solid state drive) market due to its recent acquisition of SanDisk. Although I felt the benefits from that transaction would be realized sooner than most… Read More

Juno Therapeutics (Nasdaq: JUNO), a company specializing in immunotherapy combined with chemotherapy and conventional cancer treatments,  was rallying in early trading today, just five days after a massive 30 plus percent drop in price after two unexpected deaths occurred in a critical Phase II trial for end stage leukemia patients… Read More